January 10, 2006—Pharma companies Gilead Sciences and Bristol-MyersSquibb announced yesterday that tests of the first-ever, three-in-oneanti-HIV pill showed it was as effectiveas taking the drugs separately. Gilead is applying for FDA approval ofthe pill—combining Emtriva, Viread and Sustiva—between April andJune, and hopes it will be available later this year.